The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index; 12 of the 31 sources its claims cite were checked for support.
Maintenance or Discontinuation of Antidepressants in Primary Care
Open accessAbstract
BACKGROUND Patients with depression who are treated in primary care practices may receive antidepressants for prolonged periods. Data are limited on the effects of maintaining or discontinuing antidepressant therapy in this setting. METHODS We conducted a randomized, double-blind trial involving adults who were being treated in 150 general practices in the United Kingdom. All the patients had a history of at least two depressive episodes or had been taking antidepressants for 2 years or longer and felt well enough to consider stopping antidepressants. Patients who had received citalopram, fluoxetine, sertraline, or mirtazapine were randomly assigned in a 1:1 ratio to maintain their current antidepressant therapy (maintenance group) or to taper and discontinue such therapy with the use of matching placebo (discontinuation group). The primary outcome was the first relapse of depression during the 52-week trial period, as evaluated in a time-to-event analysis. Secondary outcomes were depressive and anxiety symptoms, physical and withdrawal symptoms, quality of life, time to stopping an antidepressant or placebo, and global mood ratings. RESULTS A total of 1466 patients underwent screening. Of these patients, 478 were enrolled in the trial (238 in the maintenance group and 240 in the discontinuation group). The average age of the patients was 54 years; 73% were women. Adherence to the trial assignment was 70% in the maintenance group and 52% in the discontinuation group. By 52 we…
Overview
CoChat Summary
TL;DR
In primary care patients who felt well enough to stop long-term antidepressants, tapering to placebo led to a higher risk of depression relapse by 52 weeks than continuing maintenance therapy. Discontinuation was also associated with more depressive, anxiety, and withdrawal symptoms, though serious adverse events were similar between groups.
Key findings
- Relapse of depression by 52 weeks occurred in 92 of 238 patients (39%) in the maintenance group and 135 of 240 (56%) in the discontinuation group (hazard ratio, 2.06; 95% CI, 1.56 to 2.70; P<0.001).
- At 12 weeks, the discontinuation group had worse depressive symptoms (PHQ-9 mean, 4.1 vs. 6.3; difference, 2.2 points; 95% CI, 1.5 to 2.8), anxiety symptoms (GAD-7 mean, 3.1 vs. 5.3; difference, 2.4 points; 95% CI, 1.8 to 3.0), withdrawal symptoms (modified DESS mean, 1.3 vs. 3.1; difference, 1.9 points; 95% CI, 1.5 to 2.3), and mental health–related quality of life (SF-12 mental component mean, 46 vs. 41; difference, −4.9 points; 95% CI, −6.4 to −3.3).
- More patients in the discontinuation group stopped trial medication (48% vs. 30%; hazard ratio, 2.28; 95% CI, 1.68 to 3.08) and returned to an antidepressant prescribed by their primary care doctor (39% vs. 20%).
- Serious adverse events were similar: 9 (4%) in the maintenance group and 8 (3%) in the discontinuation group; there were no deaths or suicide attempts during the trial.
Methods
- Multicenter, randomized, double-blind trial in 150 general practices across four sites in England; adults aged 18 to 74 years were eligible if they had at least two prior depressive episodes or had taken antidepressants for more than 2 years, had been taking standard doses of citalopram, sertraline, fluoxetine, or mirtazapine for at least 9 months, had recovered from their most recent depressive episode, and felt well enough to consider stopping. Current ICD-10 depression was the main exclusion criterion.
- A total of 1466 patients underwent screening; 478 were enrolled and randomly assigned 1:1 to maintain current antidepressant therapy (n=238) or taper and discontinue with matching placebo (n=240), with 52-week follow-up.
- The primary outcome was first relapse of depression during 52 weeks, analyzed in a time-to-event analysis with Cox proportional-hazards modeling adjusted for baseline CIS-R depression score; secondary outcomes included PHQ-9, GAD-7, Toronto Side Effect Scale, modified DESS, SF-12, time to stopping medication, and global mood ratings.
Limitations
- The paper states that it investigated only three SSRIs with similar pharmacologic profiles plus mirtazapine, so findings cannot be generalized to other antidepressant classes; it excluded escitalopram and nonstandard doses; only a small percentage of invited patients participated, which may have introduced bias; findings pertain only to patients who felt ready to discontinue; the relapse measure was adapted and required retrospective assessment over 12 weeks; the population lacked ethnic diversity and was treated entirely in the U.K. health system, limiting generalizability; recall bias was possible; and detailed information about the original prescribing decision or diagnosis was unavailable.
- The paper states that there was no prespecified adjustment for multiple comparisons for secondary outcomes, so no definite conclusions can be drawn from those data.
- Evident from the text: adherence differed between groups (70% maintenance vs. 52% discontinuation), and 39% of the discontinuation group returned to antidepressants by the end of the trial, which may explain the lack of between-group differences at 52 weeks; 10 patients without timing of relapse were excluded from the primary analysis.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
5 Valid · 3 Not valid · 2 Not checked · 45 Own results and interpretations
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“We investigated only three selective serotoninreuptake inhibitors that have similar pharmacologic profiles and have similar mechanisms of activity, along with mirtazapine (a noradrenergic and specific serotonergic antidepressant), so we cannot generalize our findings to other classes”
What the sources say
- Disputedcites [23] 23. Lewis G, Duffy L, Ades A, et al. The clinical effectiveness of sertraline in primary care and the role of depression severity and duration (PANDA): a pragmatic, double-blind, placebo-controlled random ised trial. Lancet Psychiatry 2019; 6: 903-14. sourceExperimental — accuracy not yet measured
The Summary (p. 2) says the PANDA trial assigned patients to sertraline or placebo. It did not investigate three SSRIs and mirtazapine, as the citing sentence claims; the Discussion (p. 12) also describes its finding specifically in terms of sertraline. (LLM, conf=0.94)
Checked by a reasoning model — may be wrong.
- Disputedcites [26] 26. Harmer CJ, Duman RS, Cowen PJ. How do antidepressants work? New perspectives for refining future treatment approaches. Lancet Psychiatry 2017; 4: 409-18. sourceExperimental — accuracy not yet measured
The cited paper does not present a trial limited to three SSRIs and mirtazapine. Its Introduction discusses several other antidepressant classes, including norepinephrine reuptake inhibitors, bupropion, and SNRIs; the Conclusion describes a broader account of antidepressant mechanisms. No page numbers are available in our copy. (LLM, conf=0.87)
Checked by a reasoning model — may be wrong.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
Every source the paper cites for this claim was checked and supports it.
In the paper
“We determined that the enrollment of 479 patients would provide the trial with 90% power to detect a hazard ratio of 1.92 for the primary outcome in the discontinuation group on the basis of an estimated relapse frequency of 20% in the maintenance group and 35% in the discontinuation group at a two-sided alpha level of 0.05, assuming 20% attrition.”
What the sources say
- Supportedcites [24] 24. Duffy L, Bacon F, Clarke CS, et al. A randomised controlled trial assessing the use of citalopram, sertraline, fluoxetine and mirtazapine in preventing relapse in primary care patients who are taking long-term maintenance antidepressants (ANTLER: ANTidepressants to prevent reLapse in dEpRession): study protocol for a randomised controlled trial. Trials 2019; 20: 319. source
The Justification of sample size section gives 90% power at the 5% significance level for relapse rates of 20% in the continuation arm and 35% in the withdrawal arm, and proposes recruiting 479 participants after allowing for 20% attrition. Its hazard ratio of 0.52 compares continuation with withdrawal; reversing that comparison gives approximately 1.92 for withdrawal relative to continuation. (LLM, conf=0.91)
hedgedn = 479- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Several systematic reviews of studies have shown a higher rate of relapse among patients who discontinue antidepressant therapy than among those who continue to receive such therapy”
What the sources say
- Not checked — no full text of the sourcecites [6] 6. Geddes JR, Carney SM, Davies C, et al. Relapse prevention with antidepressant drug treatment in depressive disorders: a systematic review. Lancet 2003; 361: 65361. source
- Not checked — no full text of the sourcecites [7] 7. Kaymaz N, van Os J, Loonen AJM, Nolen WA. Evidence that patients with single versus recurrent depressive episodes are differentially sensitive to treatment discontinuation: a meta-analysis of placebocontrolled randomized trials. J Clin Psychiatry 2008; 69: 1423-36. source
- Not checked — no full text of the sourcecites [8] 8. Glue P, Donovan MR, Kolluri S, Emir B. Meta-analysis of relapse prevention antidepressant trials in depressive disorders. Aust N Z J Psychiatry 2010; 44: 697-705. source
- Supportedcites [9] 9. Sim K, Lau WK, Sim J, Sum MY, Baldessarini RJ. Prevention of relapse and recurrence in adults with major depressive disorder: systematic review and metaanalyses of controlled trials. Int J Neuropsychopharmacol 2015; 19(2): pyv076. source
The Results section, under “Continuation Trials of Antidepressants” (page not provided), reports relapse in 49.4% of patients after discontinuation versus 23.3% of those who continued antidepressants. This directly supports the comparison attributed to this systematic review. (LLM, conf=0.94)
- Not checked — no full text of the sourcecites [10] 10. Loonen AJM, Peer PGM, Zwanikken GJ. Continuation and maintenance therapy with antidepressive agents. Meta-analysis of research. Pharm Weekbl Sci 1991; 13: 167-75. source
- Not matchedcites [11] 11. Hansen R, Gaynes B, Thieda P, et al.
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Not checked — no full text of the sourcecites [12] 12. Williams N, Simpson AN, Simpson K, Nahas Z. Relapse rates with long-term antidepressant drug therapy: a meta-analysis. Hum Psychopharmacol 2009; 24: 401-8. source
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“and the categories of serious events were similar in the two groups (Table 3).”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The mean score for side effects as assessed on the Toronto scale at 12 weeks was 4.2±2.9 in the maintenance group and 4.6±3.0 in the discontinuation group, for an estimated difference of 0.7 points (95% CI, 0.3 to 1.1).”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
18 more claims
Create a free account to see all 55 claims and every source verdict.
- It may state two separate claims as one. 20
- Probably not a substantial claim. 17
- The quote only partly states this claim. 4
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“Thus, the differences in relapse rates between individuals with MDD who continued antidepressants that were effective during acute treatment and those who discontinued the antidepressants are still unclear.”
From Relapse and its modifiers in major depressive disorder after antidepressant discontinuation: meta-analysis and meta-regression (2023) · cites this paper as [2]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“and relapse rates at 39 weeks of 40 and 69% (29% difference), respectively [2].”
From Relapse and its modifiers in major depressive disorder after antidepressant discontinuation: meta-analysis and meta-regression (2023) · cites this paper as [2]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“These data provide the best evidence for the existence of PAWS, indicating that antidepressant withdrawal symptoms may persist up to at least 39 weeks in some patients.”
From Post-acute withdrawal syndrome (PAWS) after stopping antidepressants: a systematic review with meta-narrative synthesis (2025) · cites this paper as Lewis et al., 2021
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In this study, 39 weeks after patients had started tapering citalopram, fluoxetine, sertraline or mirtazapine, the number of recorded withdrawal symptoms was still significantly increased compared to patients maintained on their antidepressant medication.”
From Post-acute withdrawal syndrome (PAWS) after stopping antidepressants: a systematic review with meta-narrative synthesis (2025) · cites this paper as Lewis et al., 2021
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Of note, in the design of this RCT, the popular antidepressant drugs paroxetine and venlafaxine were deliberately excluded, because, as written by the authors, both are known to cause marked withdrawal symptoms when treatment is discontinued (Lewis et al., 2021; p. 1258).”
From Post-acute withdrawal syndrome (PAWS) after stopping antidepressants: a systematic review with meta-narrative synthesis (2025) · cites this paper as Lewis et al., 2021
Experimental — accuracy not yet measured
13 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Secondary Outcomes
“At 12 weeks, secondary outcomes were generally in the same direction as the primary outcome, except for scores on the SF-12 physical-health component and Toronto Side Effect Scale (Table 2).”
§ The new england journal o f medicine
“| Score on modified Toronto Side Effect Scale | | | | | 12 wk | 4.2±2.9 | 4.6±3.0 | 0.7 (0.3 to 1.1) |”
Citations
Cites
Lewis, G., Pelosi, A. J., Araya, R., & Dunn, G. (1992) · Psychological Medicine · doi:10.1017/s0033291700030415 · Cited by 1,487
Self-citationRelapse prevention with antidepressant drug treatment in depressive disorders: a systematic review
Geddes, J. R., Carney, S. M., Davies, C., Furukawa, T. A., Kupfer, D. J., Frank, E., & Goodwin, G. M. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12599-8 · Cited by 945
How do antidepressants work? New perspectives for refining future treatment approaches
Harmer, C. J., Duman, R. S., & Cowen, P. J. (2017) · The Lancet Psychiatry · doi:10.1016/s2215-0366(17)30015-9 · Cited by 616
Selective serotonin reuptake inhibitor discontinuation syndrome: a randomized clinical trial
Rosenbaum, J. F., Fava, M., Hoog, S. L., Ascroft, R. C., & Krebs, W. B. (1998) · Biological Psychiatry · doi:10.1016/s0006-3223(98)00126-7 · Cited by 574
Different ways to estimate treatment effects in randomised controlled trials
J, T., L, B., T, H., J, R., M, W., & M, H. (2018) · Contemporary Clinical Trials Communications · doi:10.1016/j.conctc.2018.03.008 · Cited by 532
Influences on antidepressant prescribing trends in the UK: 1995–2011
Mars, B., Heron, J., Kessler, D., Davies, N. M., Martin, R. M., Thomas, K. H., & Gunnell, D. (2017) · Social Psychiatry and Psychiatric Epidemiology · doi:10.1007/s00127-016-1306-4 · Cited by 419
Self-citationFive-Year Outcome for Maintenance Therapies in Recurrent Depression
Kupfer, D. J. (1992) · Archives of General Psychiatry · doi:10.1001/archpsyc.1992.01820100013002 · Cited by 370
Wiles, N., Thomas, L., Abel, A., Ridgway, N., Turner, N., Campbell, J., Garland, A., Hollinghurst, S., Jerrom, B., Kessler, D., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(12)61552-9 · Cited by 340
Self-citationMoore, M., Yuen, H. M., Dunn, N., Mullee, M. A., Maskell, J., & Kendrick, T. (2009) · BMJ · doi:10.1136/bmj.b3999 · Cited by 287
Self-citationKendrick, T., Dowrick, C., McBride, A., Howe, A., Clarke, P., Maisey, S., Moore, M., & Smith, P. W. (2009) · BMJ · doi:10.1136/bmj.b750 · Cited by 231
Self-citation
Cited by
Marx, W., Penninx, B. W. J. H., Solmi, M., Furukawa, T. A., Firth, J., Carvalho, A. F., & Berk, M. (2023) · Nature Reviews Disease Primers · doi:10.1038/s41572-023-00454-1 · Cited by 768
“Ongoing prescription of antidepressants should be routinely re-evaluated to prevent relapse, which is more frequent after discontinuation of antidepressants 209 , to ensure the medication is still effective, and that the benefit of treatment outweighs potential adverse effects.”
Novel and emerging treatments for major depression
Marwaha, S., Palmer, E., Suppes, T., Cons, E., Young, A. H., & Upthegrove, R. (2023) · The Lancet · doi:10.1016/s0140-6736(22)02080-3 · Cited by 588
Lam, R. W., Kennedy, S. H., Adams, C., Bahji, A., Beaulieu, S., Bhat, V., Blier, P., Blumberger, D. M., Brietzke, E., Chakrabarty, T., et al. (2024) · The Canadian Journal of Psychiatry · doi:10.1177/07067437241245384 · Cited by 369
British Society of Gastroenterology guidelines on the management of functional dyspepsia
Black, C. J., Paine, P. A., Agrawal, A., Aziz, I., Eugenicos, M. P., Houghton, L. A., Hungin, P., Overshott, R., Vasant, D. H., Rudd, S., et al. (2022) · Gut · doi:10.1136/gutjnl-2022-327737 · Cited by 193
Adverse Effects of Antidepressant Medications and their Management in Children and Adolescents
Strawn, J. R., Mills, J. A., Poweleit, E. A., Ramsey, L. B., & Croarkin, P. E. (2023) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.2767 · Cited by 185
Metadata
- Authors
- Lewis, G., Marston, L., Duffy, L., Freemantle, N., Gilbody, S., Hunter, R., Kendrick, T., Kessler, D., Mangin, D., King, M., Lanham, P., Moore, M., Nazareth, I., Wiles, N., Bacon, F., Bird, M., Brabyn, S., Burns, A., Clarke, C. S., Hunt, A., Pervin, J., & Lewis, G.
- Affiliations
- University of Bristol (GB)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2021-09-30
- Volume
- 385
- Issue
- 14
- Pages
- 1257-1267
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W3204219363
- Cited by
- 192
- References
- 25
- Citations by year
- 2026: 33 · 2025: 42 · 2024: 44 · 2023: 35 · 2022: 27 · 2021: 10
- FWCI
- 16.93
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Explore Bristol Research (publishedVersion, other-oa)
- White Rose Research Online (University of Leeds, The University of Sheffield, University of York) (acceptedVersion)
- Liverpool John Moores University (acceptedVersion)
- ePrints Soton (University of Southampton) (submittedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Bristol Research (University of Bristol) (submittedVersion, other-oa)
- Funders
- Health Technology Assessment Programme (13/115/48)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Mental Health Treatment and Access
- Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
- Keywords
- antidepressant discontinuation, antidepressant tapering, depression relapse, long-term antidepressant use, citalopram, fluoxetine, sertraline, mirtazapine, withdrawal symptoms, primary care depression, quality of life
- MeSH terms
- Adult, Aged, Antidepressive Agents, Anxiety Disorders, Depressive Disorder, Double-Blind Method, Female, Follow-Up Studies, United Kingdom, Humans, Male, Middle Aged, Primary Health Care, Surveys and Questionnaires, Recurrence, Citalopram, Selective Serotonin Reuptake Inhibitors, Withholding Treatment, Kaplan-Meier Estimate, Maintenance Chemotherapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-12, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-12 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Maintenance or Discontinuation of Antidepressants in Primary Care. https://app.cochat.ai/papers/10.1056/nejmoa2106356
- The paper
- Lewis, G., Marston, L., Duffy, L., Freemantle, N., Gilbody, S., Hunter, R., Kendrick, T., Kessler, D., Mangin, D., King, M., Lanham, P., Moore, M., Nazareth, I., Wiles, N., Bacon, F., Bird, M., Brabyn, S., Burns, A., Clarke, C. S., . . . Lewis, G. (2021). Maintenance or Discontinuation of Antidepressants in Primary Care. New England Journal of Medicine. https://doi.org/10.1056/nejmoa2106356
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.